Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats

Open access


Simvastatin is poorly bioavailable because it is practically insoluble in water and shows dissolution rate-limited absorption. Solubilizing effects of several β-cyclodextrin (βCD) derivatives such as HPβCD, SBEβCD and DMβCD on simvastatin in aqueous solution were investigated using the phase solubility technique. The solubility diagram of simvastatin with each βCD derivative could be classified as AL-type, indicating soluble complex formation of 1:1 stoichiometry. Among the above βCD derivatives DMβCD was found to be the ideal complexing agent for improving drug solubility. The simvastatin complex with DMβCD was prepared using the co-evaporation method and was then characterized by differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FT-IR) and in vitro dissolution. Dissolution and pharmacokinetic studies indicated that the simvastatin/DMβCD complex exhibited an increased dissolution rate, rapid absorption, and improved bioavailability in rats compared to free drug. Maximum plasma concentration (cmax) and the time to reach it (tmax) were 21.86 μg mL−1 and 1.4 h for the drug complex, 8.25 μg mL−1 and 3.0 h for free drug, respectively. Main pharmacokinetic parameters such as tmax, cmax were significantly different (p < 0.01) between the simvastatin complex and free drug. Bioavailability of the simvastatin complex relative to free drug was up to 167.0 %.


  • 1. G. A. McClelland, R. J. Stubbs, J. A. Fix, S. A. Pogany and G. M. Zentner, Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reducase inhibitor efficacy through administration of a controlled porosity osmotic pump dosage form, Pharm. Res. 8 (1991) 873–876;

  • 2. A. A. Anshuman, K. R. Mahadik and A. Paradkar, Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: In vitro and in vivo evaluations, Pharm. Res. 22 (2005) 990–998;

  • 3. M. Schachter, Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update, Fundam. Clin. Pharmacol. 19 (2005) 117–125;

  • 4. A. Fattahi, J. Karimi-Sabet, A. Keshavarz, A. Golzary, M. Rafiee-Tehrani and F. A. Dorkoosh, Preparation and characterization of simvastatin nanoparticles using rapid expansion of supercritical solution (RESS) with trifluoromethane, J. Supercrit. Fluids 107 (2016) 469–478;

  • 5. J. K. Patel and V. B. Sutariya, Micronisation of simvastatin by the supercritical antisolvent technique: in vitro-in vivo evaluation, J. Microencapsul. 32 (2015) 193–200;

  • 6. P. A. Sonar, A. L. Behera, S. K. Banerjee, D. D. Gaikwad and S. L. Harer, Preparation and characterization of simvastatin solid dispersion using skimmed milk, Drug Dev. Ind. Pharm. 41 (2015) 22–27;

  • 7. K. M. Hosny, A. Khames and S. S. A. Elhady, Preparation and evaluation of orodispersible tablets containing hydroxylbutyl-beta-cyclodextrin-simvastatin solid dispersion, Trop. J. Pharm. Res. 12 (2013) 469–476;

  • 8. S. D. Saoji, V. S. Belgamwar, S. S. Dharashivkar, A. A. Rode, C. Mack and V. S. Dave, The study of the influence of formulation and process variables on the functional attributes of simvastatin-phospholipid complex, J. Pharm. Innov. 11 (2016) 264–278;

  • 9. G. Abdelbary, M. Amin and S. Salah, Self nano-emulsifying simvastatin based tablets: design and in vitro/in vivo evaluation, Pharm. Dev. Technol. 18 (2013) 1294–1304;

  • 10. Z. W. Zhang, H. H. Bu, Z. W. Gao, Y. Huang, F. Gao and Y. P. Li, The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats, Int. J. Pharm. 394 (2010) 147–153;

  • 11. B. K. Kang, J. S. Lee, S. K. Chon, S. Y. Jeong, S. H. Yuk, G. Khang, H. B. Lee and S. H. Cho, Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs, Int. J. Pharm. 274 (2004) 65–73;

  • 12. A. Porfire, D. Muntean, M. Achim, L. Vlase and I. Tomuta, Simultaneous quantification of simvastatin and excipients in liposomes using near infrared spectroscopy and chemometry, J. Pharm. Biomed. Anal. 107 (2015) 40–49;

  • 13. V. J. Stella and Q. He, Cyclodextrins, Toxicol. Pathol. 36 (2008) 30–42;

  • 14. J. Pitha, J. Milecki, H. Fales, L. Pannell and K. Uekama, Hydroxypropyl-β-cyclodextrin: preparation and characterization; effect on solubility of drugs, Int. J. Pharm. 29 (1986) 73–82;

  • 15. C. Jullian, Improvement of galangin solubility using native and derivative cyclodextrin. An UV-vis and NMR study, J. Chil. Chem. Soc. 54 (2009) 201–203;

  • 16. Y. Kwon, H. Kim, S. Park and S. Jung, Enhancement of solubility and antioxidant activity of some flavonoids based on the inclusion complexation with sulfobutylether beta-cyclodextrin, Bull. Korean Chem. Soc. 31 (2010) 3035–3037;

  • 17. X. H. Wen, Z. Y. Liu and T. Q. Zhu, Mass spectrometry and molecular modeling studies on the inclusion complexes between α, β-cyclodextrins and simvastatin, Chem. Phys. Lett. 405 (2005) 114–117;

  • 18. F. Csempesz, A. Süle and I. Puskás, Induced surface activity of supramolecular cyclodextrin-statin complexes: Relevance in drug delivery, Coll. Surf. A. 354 (2010) 308–313;

  • 19. S. W. Jun, M. S. Kim, J. S. Kim, H. J. Park, S. Lee, J. S. Woo and S. J. Hwang, Preparation and characterization of simvastatin/hydroxylpropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process, Eur. J. Pharm. Biopharm. 66 (2007) 413–421;

  • 20. L. X. Zhang, Y. X. Zhang, L. Zhang and Y. H. Chen, Preparation of simvastatin orally disintegrating tablets and its quality evaluation, Chin. J. New Drugs 17 (2008) 766–768;

  • 21. T. Higuchi and K. A. Connors, Phase solubility techniques, Adv. Anal. Chem. Instrum. 4 (1965) 117–212.

  • 22. C. Mendes, A. Buttchevitz, J. H. Kruger, J. M. Kratz, C. M. O. Simoes, P. D. Benedet, P. R. Oliveira and M. A. S. Silva, Inclusion complexes of hydrochlorothiazide and beta-cyclodextrin: Physicochemical characteristics, in vitro and in vivo studies, Eur. J. Pharm. Sci. 83 (2016) 71–78;

  • 23. Y. M. Liu, X. F. Wang and D. Wang, Preparation and pharmacokinetics in rats of simvastatin solid lipid nanoparticles, Chin. Pharmacist. 19 (2016) 50–53;

  • 24. L. Tan, L. L. Yang, X. Zhang, Y. S. Yuan and S. S. Ling, Determination of simvastatin in human plasma by high performance liquid chromatography, Chin. J. Chromatogr. 18 (2000) 232–234;

  • 25. F. Ungaro, C. Giovino, O. Catanzano, A. Miro, A. Mele, F. Quaglia and M. I. La Rotonda, Use of cyclodextrins as solubilizing agents for simvastatin: Effect of hydroxylpropyl-β-cyclodextrin on lactone/hydroxyacid aqueous equilibrium, Int. J. Pharm. 404 (2011) 49–56.

  • 26. M. Yamamoto, F. Hirayama and K. Uekama, Improvement of stability and dissolusion of prostaglandin E1 by maltosyl-β-cyclodexrtin in lyophilized formulation, Chem. Pharm. Bull. 40 (1992) 747–751;

  • 27. A. Sule, L. Szente and F. Csempesz, Enhancement of drug solubility in supramolecular and colloidal systems, J. Pharm. Sci. 98 (2009) 484–494;

  • 28. M. J. Arias, J. R. Moyano and J. M. Ginés, Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding, Int. J. Pharm. 153 (1997) 181–189;

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information

IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 26 26 26
PDF Downloads 7 7 7